1. Market Research
  2. > Pharmaceutical Market Trends
  3. > VentiRx Pharmaceuticals, Inc. - Product Pipeline Review - 2015

VentiRx Pharmaceuticals, Inc. - Product Pipeline Review - 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 29 pages

VentiRx Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘VentiRx Pharmaceuticals, Inc. - Product Pipeline Review - 2015’, provides an overview of the VentiRx Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of VentiRx Pharmaceuticals, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of VentiRx Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of VentiRx Pharmaceuticals, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the VentiRx Pharmaceuticals, Inc.’s pipeline products

Reasons to buy

- Evaluate VentiRx Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of VentiRx Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the VentiRx Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of VentiRx Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of VentiRx Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of VentiRx Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

VentiRx Pharmaceuticals, Inc. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
VentiRx Pharmaceuticals, Inc. Snapshot 5
VentiRx Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
VentiRx Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
VentiRx Pharmaceuticals, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
VentiRx Pharmaceuticals, Inc. - Pipeline Products Glance 10
VentiRx Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
VentiRx Pharmaceuticals, Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
VentiRx Pharmaceuticals, Inc. - Drug Profiles 14
motolimod 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
VTX-1463 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
VTX-378 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
VTX-294 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
VentiRx Pharmaceuticals, Inc. - Pipeline Analysis 20
VentiRx Pharmaceuticals, Inc. - Pipeline Products by Target 20
VentiRx Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 21
VentiRx Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 22
VentiRx Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 23
VentiRx Pharmaceuticals, Inc. - Recent Pipeline Updates 24
VentiRx Pharmaceuticals, Inc. - Dormant Projects 26
VentiRx Pharmaceuticals, Inc. - Locations And Subsidiaries 27
Head Office 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 28
Disclaimer 29

List of Tables
VentiRx Pharmaceuticals, Inc., Key Information 5
VentiRx Pharmaceuticals, Inc., Key Facts 5
VentiRx Pharmaceuticals, Inc. - Pipeline by Indication, 2015 7
VentiRx Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 8
VentiRx Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 9
VentiRx Pharmaceuticals, Inc. - Phase II, 2015 10
VentiRx Pharmaceuticals, Inc. - Phase I, 2015 11
VentiRx Pharmaceuticals, Inc. - Preclinical, 2015 12
VentiRx Pharmaceuticals, Inc. - Discovery, 2015 13
VentiRx Pharmaceuticals, Inc. - Pipeline by Target, 2015 20
VentiRx Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015 21
VentiRx Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015 22
VentiRx Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015 23
VentiRx Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015 24
VentiRx Pharmaceuticals, Inc. - Dormant Developmental Projects,2015 26

List of Figures
VentiRx Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015 7
VentiRx Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 8
VentiRx Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 9
VentiRx Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015 20
VentiRx Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015 21
VentiRx Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015 22
VentiRx Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.